Cathepsin cysteine protease inhibitors

A compound, alkyl technology, applied in the field of cathepsin cysteine ​​protease inhibitors, can solve problems such as inactivity

Inactive Publication Date: 2007-02-28
MERCK FROSST CANADA INC
View PDF34 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

All mutations identified to date in the cathepsin K gene are known to result in an inactive protein

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cathepsin cysteine protease inhibitors
  • Cathepsin cysteine protease inhibitors
  • Cathepsin cysteine protease inhibitors

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0218] N 1 -(2-oxotetrahydrofuran-3-yl)-N 2 -{(1S)-2,2,2-Trifluoro-1-[4'-(methylsulfonyl)biphenyl-4-yl]ethyl}-L-leucinamide

[0219]

[0220] Under stirring at room temperature within 30 minutes, to N-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)biphenyl-4-yl]ethyl}-L - Leucine (30 mg, 68 μmol), benzotriazol-1-yl-oxotripyrrophosphine hexafluorophosphate (40 mg, 77 μmol) and α-amino-γ-butyrolactone (26 mg, 140 μmol) in DMF (0.20ml) was added triethylamine (30μl, 220μmol). The mixture was partitioned between ethyl acetate and water and the layers were separated. The organic phase was washed with brine, dried (sodium sulfate) and concentrated, and purified by flash chromatography on silica gel eluting with ethyl acetate to afford the title compound as a colorless solid. MS(+ESI):527.2(M+1) + .

[0221] h 1 NMR (acetone-d 6 , 500MHz) δ8.06 (4H, d), 8.00-7.95 (4H, m), 7.90 (1H, m), 7.83 (1H, overlapping m), 7.80 (4H, d), 7.67 (4H, t), 4.58(2H,m), 4.45(2H,m), 4.37(2H,m),...

Embodiment 2

[0223] N 1 -[2-Oxo-1-(phenylsulfonyl)pyrrolidin-3-yl]-N2 -{(1S)-2,2,2-Trifluoro-1-[4'-(methylsulfonyl)biphenyl-4-yl]ethyl}-L-leucinamide

[0224]

[0225] Under stirring at room temperature within 2.5 hours, to N-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)biphenyl-4-yl]ethyl}-L -Leucine (40 mg, 90 μmol), benzotriazol-1-yl-oxotripyrrophosphine hexafluorophosphate (55 mg, 110 μmol) and (54 mg, 220 μmol) in DMF (0.2ml) were added tris Ethylamine (30 μl, 220 μmol). The mixture was partitioned between ethyl acetate and water and the layers were separated. The organic phase was washed with brine, dried (sodium sulfate) and concentrated, and purified by flash chromatography on silica gel eluting with 3 / 2 ethyl acetate / hexanes to give the title compound as a colorless thick syrup. MS(+ESI):666.3(M+1) + .

[0226] h 1 NMR (acetone-d 6 , 500MHz) δ8.07-7.97 (8H, d), 7.96-7.92 (4H, m), 7.86-7.70 (8H, m), 7.65-7.57 (8H, m), 4.54 (2H, m), 4.40 ( 2H, m), 3.93 (2H, m), 3.80 (2H, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to a novel class of compounds mainly, substituted leucinamide-carboxylate derivatives of formula (I) wherein X is O or NR<9>, Y is CR<1>R<2>, -SO<2>, C=O or NR<9>; Z is CR<1>R<2>, O, S, -SO2 or NR<9> and each G is independently a CR<1>CR<2> and pharmaceutical compositions thereof. Said compounds are cathepsin cysteine protease inhibitors, including but not limited to, inhibitors of cathepsin K, L, S and B. These compounds are useful for treating and preventing cathpesin dependent conditions in which inhibition of bone resorption is indicated, such as osteoporosis.

Description

Background of the invention [0001] A number of disorders in humans and other mammals involve or are associated with abnormal bone resorption. Such disorders include, but are not limited to, osteoporosis, glucocorticoid-induced osteoporosis, Paget's disease, abnormally increased bone turnover, periodontal disease, tooth loss, bone fractures, atherosclerosis, obesity, parasites Infection, rheumatoid arthritis, osteoarthritis, periprosthetic osteolysis, incomplete osteogenesis, metastatic bone disease, malignant hypercalcemia, and multiple myeloma. One of the most common of these diseases is osteoporosis, which most commonly occurs in postmenopausal women. Osteoporosis is a systemic skeletal disorder characterized by low bone mass and deterioration of the microarchitecture of bone tissue, with consequent increased bone fragility and susceptibility to fracture. Osteoporotic fractures are the leading cause of morbidity and mortality in the elderly population. Because osteoporosi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61P19/08C07D207/26C07D307/33C07D207/273
CPCC07D307/33C07D207/273A61P1/02A61P19/02A61P19/08A61P19/10A61P29/00A61P3/04A61P3/06A61P43/00A61P9/10
Inventor C·贝利S·N·克兰S·莱格尔
Owner MERCK FROSST CANADA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap